Rita Jain - 05 Jan 2026 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Reporting relationship: Director
Issuer ticker: SABS
Reported as of: 05 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Jan 2026, 16:41:02 UTC
Prior SEC filing: 05 Jan 2026
Next SEC filing: 08 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Grant Levine, attorney-in-fact

Key filing fact

Rita Jain filed Form 4 for SAB Biotherapeutics, Inc. (SABS) on 07 Jan 2026.

Key facts

This page summarizes Rita Jain's Form 4 filing for SAB Biotherapeutics, Inc. (SABS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Jan 2026, 16:41.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001707797 Primary reporting owner

Jain Rita

Relationship: Director
Address: 777 W 41ST STREET, SUITE 401, MIAMI BEACH
Signature: /s/ Grant Levine, attorney-in-fact
Signature date: 07 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SABS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +240,000
Change %
Price: $0.000000
Shares after: 240,000
Date: 05 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 240,000
Exercise price: $3.74
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029.

Footnote F2

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.